Full-Time

Senior Procurement Manager

Research & Development

Posted on 11/11/2025

Deadline 11/24/25
Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Hyderabad, Telangana, India

In Person

Category
Operations & Logistics (1)
Requirements
  • University degree; Life Science degree preferable
  • Extensive experience in sourcing, simple contracting, people management, operational efficiency projects, or relevant commodity experience
  • Proven capability in negotiating project budgets and contracts
  • Demonstrated project management skills
  • Proven leadership skills with ability to motivate and influence
  • Business level fluency in English
Responsibilities
  • Sourcing and category subject matter specialist conducting internal analysis to develop and implement strategies and tactical plans for Roche to source and negotiate for third-party goods and services that satisfy stakeholder requirements
  • Procurement practitioner delivering and executing sourcing strategies by leveraging spend, category know-how, robust sourcing, negotiation, contracting, supplier management, and project management skills to achieve objectives and key results
  • Content and automation advocate translating sourcing outcomes and opportunities into content and automated buying channels that improve business adoption, satisfaction, and overall efficiency
  • Manage day to day operations of the R&D team, organizing and overseeing workload, team statistics, information and trainings
  • Lead the local R&D team meetings, virtual and on-site
  • 1 on 1 check-ins with the local R&D team
  • Act as the local R&D team’s main point of contact for sourcing and contracting queries, supporting the team's training and knowledge sharing (clarifying sourcing questions, ensuring quality of contracts and due diligence, organizing meetings with Category Managers when needed and organizing internal training for the team, supporting the team spirit and motivation)
  • Collaborate cross functionally with other Procurement teams to share knowledge and improve Stakeholder support
  • Understand processes and support requests across multiple R&D categories (Clinical Trial management, Clinical Biomarkers, and Pre-clinical Research Services)
  • Follow global sourcing and contracting strategies to ensure alignment across regions
  • Manage team recruitments, onboarding and training of new starters
  • Participate in monthly Regional R&D Meetings, supporting initiatives and proposing ideas to streamline work and processes
  • Ensure correct usage of myBuy Sourcing & Contracting platform by local R&D team, and myBuy Navigator by Stakeholders, providing support as needed
Desired Qualifications
  • Knowledge in procurement systems and operational processes, such as contracting, e-Sourcing, and spot buying
  • Knowledge in the Clinical Development and/or Clinical Technologies area (e.g. Clinical Research Organisations, Imaging, eCOA, etc.)
  • Knowledge in the pre-clinical area (e.g. in vitro research, animal breeding, PK/PD)
  • Experience supporting Life Science research scientists (eg. biologist, biochemist)
  • Is open-minded and inclusive, generously sharing ideas and knowledge while being receptive to ideas and feedback from others
  • The ability to explain general capability area information to others or collect/translate moderate complexity stakeholder requirements in straightforward situations
  • Ability to act as an enterprise thinker and leverage knowledge and expertise to create solutions for business customers by proactively fostering collaboration, including across the procurement network
  • Action-oriented and can make decisions and influence others to do the same; repurpose work and ideas in favor of starting from scratch
  • Demonstrated curiosity, active listening, and a willingness to experiment and test new ideas when appropriate, focusing on continuous learning and improvement
  • We work with colleagues across procurement, business, and the broader Roche organization to broaden knowledge and expertise, better understand customer needs, and connect the dots
  • Business level fluency in English

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • PathAI acquisition for $750M in 2026 scales AI-driven digital pathology globally.
  • C4 Therapeutics DAC partnership yields up to $1B in next-gen cancer therapies.
  • CT-388 weight-loss drug targets double-digit share against Novo Nordisk, Eli Lilly.

What critics are saying

  • Swiss franc appreciation erodes 70% international revenue immediately.
  • Avastin, Herceptin patents expire 2028, Amgen biosimilars capture 50% share.
  • Tempus-Epic AI pathology platform steals 30% deals from PathAI by Q3 2026.

What makes Roche unique

  • Pioneered mass production of synthetic vitamin C in 1934 as Redoxon.
  • Acquired Genentech majority stake in 1990, entering biotechnology leadership.
  • Secured PCR technology rights from Cetus in 1991 for diagnostics dominance.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE